COVID-19As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
As a critical part of the health care community in the UK, the pharmaceutical industry continues to play the biggest possible role in the response to COVID-19.
This COVID-19 hub gives you access to the most up-to-date information for what pharmaceutical companies are doing to tackle the pandemic.
As part of the health community, pharmaceutical companies want to play as big a role as possible in the response to COVID–19. Dr Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry
Pharmaceutical companies have worked to combat a range of infectious diseases such as MERS, SARS, Ebola, influenza and COVID-19.
At the middle of December 2021, there are more than 332 medicines in various stages of development. (Source: Milken Institute)
Meanwhile there are more than 130 vaccines in clinical development, and 194 more in pre-clinical. (Source: World Health Organisation)
As well as working with health authorities and regulators to create the medicines and vaccines that are needed, we’re also working with the Government to mitigate the impact that coronavirus may have on our everyday activities.
Our members are not currently reporting any concerns about shortages of medicines that relate to the loss of manufacturing capacity as a result of COVID–19 restrictions.
There are robust procedures in place to manage the supply of medicines in the UK, and companies will be taking all possible measures to secure supply for patients - in line with Government guidance.